ストックスクリーナーアプリを入手
32.32
1.13%
-0.37
アフターアワーズ：
32.32
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Ionis Pharmaceuticals targets multibillion-dollar revenue potential with TRYNGOLZA and new launches - MSN
Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James - Yahoo Finance
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control - BioSpace
Ionis Earnings: Tryngolza Commercial Launch Underway; Shares Very Undervalued - Morningstar
Ionis posts Q4 beat as revenue base widens - MSN
Ionis Pharmaceuticals price target lowered to $38 from $45 at Stifel - MSN
What Analysts Are Saying About Ionis Pharmaceuticals Stock - Benzinga
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus - MSN
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat - Morningstar
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2024 Earnings Call Transcript - Insider Monkey
Ionis stock target cut to $60 by Raymond James - Investing.com India
Ionis presents new data on HAE drug donidalorsen - Investing.com
Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Simply Wall St
Can This New HAE Treatment Transform Patient Care? Key Clinical Data Revealed - StockTitan
Ionis Pharmaceuticals Reports Strong 2024 Results - TipRanks
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Ionis Pharmaceuticals: Q4 Earnings Snapshot - CT Insider
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Pharmaceuticals: Positive Sentiment in Earnings Call - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Quotes, Forecast and News Summary - Benzinga
Stifel cuts Ionis Pharmaceuticals target to $38, maintains Hold - Investing.com India
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval (IONS) - Seeking Alpha
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales - AOL
Ionis Pharma Beats Expectations for Q4 - The Motley Fool
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts - Investing.com
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Ionis stock gains on Q4 beat (IONS:NASDAQ) - Seeking Alpha
Ionis reports fourth quarter and full year 2024 financial results - BioSpace
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Ionis Pharmaceuticals Q4 Net Loss Widens, Revenue Falls; 2025 Sales Guidance Set - Marketscreener.com
IONIS PHARMACEUTICALS Earnings Results: $IONS Reports Quarterly Earnings - Nasdaq
Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus - Investing.com Nigeria
Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus By Investing.com - Investing.com South Africa
BRIEF-Ionis Pharmaceuticals Q4 Revenue USD 227 Million Vs. IBES Estimate USD 137.6 Million - TradingView
Can Ionis' New Drug Launches Offset Its Revenue Decline? Q4 Earnings Deep Dive - StockTitan
Ionis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In January - Insider Monkey
10 Top Insider Stock Buys And Sells In January - Insider Monkey
Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have endured a 44% loss from investing in the stock five years ago - Simply Wall St
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
How to Take Advantage of moves in (IONS) - Stock Traders Daily
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS - Nasdaq
Ionis stock rises on FDA, EMA nod for SMA drug dose increase - MSN
Ionis Pharmaceuticals (IONS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Sovran Advisors LLC Makes New $5.62 Million Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Ionis Pharma stock hits 52-week low at $30.86 By Investing.com - Investing.com Australia
Ionis Pharma stock hits 52-week low at $30.86 - MSN
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? - Nasdaq
abrdn plc Has $14.03 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):